Neural tube defect
Neural tube defect
Main page
1905195

Neural tube defect

logo
Community Hub0 subscribers
Read side by side
Neural tube defect
View on Wikipedia
from Wikipedia
Neural tube defect
Illustration of a child with spina bifida, the most common NTD
SpecialtyMedical genetics

Neural tube defects (NTDs) are a group of birth defects in which an opening in the spine or cranium remains from early in human development. In the third week of pregnancy called gastrulation, specialized cells on the dorsal side of the embryo begin to change shape and form the neural tube. When the neural tube does not close completely, an NTD develops.

Specific types include: spina bifida which affects the spine, anencephaly which results in little to no brain, encephalocele which affects the skull, and iniencephaly which results in severe neck problems.[1]

NTDs are one of the most common birth defects, affecting over 300,000 births each year worldwide.[2] For example, spina bifida affects approximately 1,500 births annually in the United States, or about 3.5 in every 10,000 (0.035% of US births),[1][3] which has decreased from around 5 per 10,000 (0.05% of US births) since folate fortification of grain products was started.[3] The number of deaths in the US each year due to neural tube defects also declined from 1,200 before folate fortification was started to 840.[4]

Types

[edit]

There are two classes of NTDs: open, which are more common, and closed. Open NTDs occur when the brain and/or spinal cord are exposed at birth through a defect in the skull or vertebrae (spinal column). Open NTDs include anencephaly, encephaloceles, hydranencephaly, iniencephaly, schizencephaly, and the most common form, spina bifida. Closed NTDs occur when the spinal defect is covered by skin. Types of closed NTDs include lipomeningocele, lipomyelomeningocele, and tethered cord.[5]

Anencephaly

[edit]

Anencephaly (without brain) is a severe neural tube defect that occurs when the anterior-most end of the neural tube fails to close, usually during the 23rd and 26th days of pregnancy. This results in an absence of a major portion of the brain and skull. Infants born with this condition lack the main part of the forebrain and are usually blind, deaf and display major craniofacial anomalies. The lack of a functioning cerebrum will prevent the infant from even gaining consciousness. Infants are either stillborn or usually die within a few hours or days after birth.[6] For example, anencephaly in humans can result from mutations in the NUAK2 kinase.[7]

Encephaloceles

[edit]

Encephaloceles are characterized by protrusions of the brain through the skull that are sac-like and covered with membrane. They can be a groove down the middle of the upper part of the skull, between the forehead and nose, or the back of the skull.[8] Due to the range in its location, encephaloceles are classified by the location as well as the type of defect it causes. Subtypes include occipital encephalocele, encephalocele of the cranial vault, and nasal encephaloceles (frontoethmoidal encephaloceles and basal encephaloceles), with approximately 80% of all encephaloceles occurring in the occipital area.[9] Encephaloceles are often obvious and diagnosed immediately. Sometimes small encephaloceles in the nasal and forehead are undetected.[10] Despite the wide range in its implications, encephaloceles are most likely to be caused by improper separation of the surface ectoderm and the neuroectoderm after the closure of the neural folds in the fourth week of gastrulation.[11]

Hydranencephaly

[edit]

Hydranencephaly is a condition in which the cerebral hemispheres are missing and instead filled with sacs of cerebrospinal fluid. People are born with hydranencephaly, but most of the time, the symptoms appear in a later stage. Newborns with hydrancephaly can swallow, cry, sleep and their head is in proportion to their body.[12] However, after a few weeks, the infants develop increased muscle tone and irritability. After a few months, the brain start to fill with cerebrospinal fluid (hydrocephalus). This has several consequences. Infants start to develop problems with seeing, hearing, growing, and learning. The missing parts of the brain and the amount of cerebrospinal fluid can also lead to seizures, spasm, problems with regulating their body temperature, and breathing and digestion problems. Besides problems in the brain, hydranencephaly can also be seen on the outside of the body. Hydrocephalus leads to more cerebrospinal fluid in the brain, which can result in an enlarged head.[13][14]

The cause of hydranencephaly is not clear. Hydranencephaly is a result of an injury of the nervous system or an abnormal development of the nervous system. The neural tube closes in the sixth week of the pregnancy,[15] so hydranencephaly develops during these weeks of the pregnancy. The cause of these injuries/development is not clear.[16]

Theories regarding the causes of hydrancephaly include:

  • blockage in the carotid artery: some researchers think that a blockage of the carotid artery leads to the under-/no development of the brain.[medical citation needed]
  • inherited condition.
  • infections: during the pregnancy, a woman can develop an infection in the uterus what can lead to problems with the neural tube.[medical citation needed]
  • environmental toxins: during the pregnancy, a woman can be exposed to environmental toxins that may have effect on the health of the infant.[medical citation needed]

Iniencephaly

[edit]

Iniencephaly is a rare neural tube defect that results in extreme bending of the head to the spine. The diagnosis can usually be made on antenatal ultrasound scanning, but if not will undoubtedly be made immediately after birth because the head is bent backwards and the face looks upwards. Usually the neck is absent. The skin of the face connects directly to the chest and the scalp connects to the upper back. Individuals with iniencephaly generally die within a few hours after birth.[17]

Spina bifida

[edit]

Spina bifida is further divided into two subclasses, spina bifida cystica and spina bifida occulta.[18]

  • Spina bifida cystica includes meningocele and myelomeningocele. Meningocele is less severe and is characterized by herniation of the meninges, but not the spinal cord, through the opening in the spinal canal. Myelomeningocele involves herniation of the meninges as well as the spinal cord through the opening.[19]
  • Spina bifida occulta means hidden split spine.[20] In this type of neural tube defect, the meninges do not herniate through the opening in the spinal canal.[19] The most frequently seen form of spina bifida occulta is when parts of the bones of the spine, called the spinous process, and the neural arch appear abnormal on a radiogram, without involvement of the spinal cord and spinal nerves.[21] The risk of recurrence in those who have a first degree relative (a parent or sibling) is 5–10 times greater compared to the general population.[22]

Causes

[edit]

Folate deficiency

[edit]

Inadequate levels of folate (vitamin B9) and vitamin B12 during pregnancy have been found to lead to increased risk of NTDs.[23][24] Although both are part of the same biopathway, folate deficiency is much more common and therefore more of a concern.[23][24] Folate is required for the production and maintenance of new cells, for DNA synthesis and RNA synthesis. Folate is needed to carry one carbon groups for methylation and nucleic acid synthesis. It has been hypothesized that the early human embryo may be particularly vulnerable to folate deficiency due to differences of the functional enzymes in this pathway during embryogenesis combined with high demand for post translational methylations of the cytoskeleton in neural cells during neural tube closure.[25] Failure of post-translational methylation of the cytoskeleton, required for differentiation has been implicated in neural tube defects.[26] Vitamin B12 is also an important receptor in the folate biopathway such that studies have shown deficiency in vitamin B12 contributes to risk of NTDs as well.[27] There is substantial evidence that direct folic supplementation increases blood serum levels of bioavailable folate even though at least one study have shown slow and variable activity of dihydrofolate reductase in human liver.[28][29] A diet rich in natural folate (350 μg/d) can show as much increase in plasma folate as taking low levels of folic acid (250 μg/d) in individuals[30] However a comparison of general population outcomes across many countries with different approaches to increasing folate consumption has found that only general food fortification with folic acid reduces neural tube defects.[31] While there have been concerns about folic acid supplementation being linked to an increased risk for cancer, a systematic review in 2012 shows there is no evidence except in the case of prostate cancer which indicates a modest reduction in risk.[32]

Choline, closely linked to folate metabolism, is essential for fetal development and is tenfold enriched in amniotic fluid compared to maternal serum levels. Its deficiency is strongly associated with NTDs, possibly due to hypomethylation in fetal progenitor cells or impaired acetylcholine synthesis, which may regulate neuronal growth and differentiation.[33] Studies in mice show that perinatal choline supplementation reduces neurodevelopmental abnormalities and improves memory, spatial skills, and exploratory behavior in offspring.[33]

There have been studies showing the relationship between NTDs, folate deficiency and the difference of skin pigmentation within human populations across different latitudes. There are many factors that would influence the folate levels in human bodies: (i) the direct dietary intake of folic acid through fortified products, (ii) environmental agents such as UV radiation. In concern with the latter, the UV radiation-induced folate photolysis has been shown via in vitro and in vivo studies to decrease the folate level and implicate in etiology of NTDs not only in humans but other amphibian species. Therefore, a protection against the UV radiation-induced photolysis of folate is imperative for the evolution of human populations living in tropical regions where the exposure to UV radiation is high over the year. One body natural adaptation is to elevate the concentration of melanin inside the skin. Melanin works as either an optical filter to disperse the incoming UV radiation rays or free radical to stabilize the hazardous photochemical products. Multiple studies have demonstrated the highly melanized integument as a defense against folate photolysis in Native Americans or African Americans correlates with lower occurrence of NTDs in general.[34][35]

Genetic deficiencies

[edit]

As reported by Bruno Reversade and colleagues, the inactivation of the NUAK2 kinase in humans leads to anencephaly.[7] This fatal birth defect is believed to arise as a consequence of impaired HIPPO signalling.[7] Other genes such as TRIM36 have also been associated with anencephaly in humans.[36]

Gene-environment interaction

[edit]

A deficiency of folate itself does not cause neural tube defects. The association seen between reduced neural tube defects and folic acid supplementation is due to a gene-environment interaction such as vulnerability caused by the C677T methylenetetrahydrofolate reductase (MTHFR) variant. Supplementing folic acid during pregnancy reduces the prevalence of NTDs by not exposing this otherwise sub-clinical mutation to aggravating conditions.[37] Other potential causes can include folate antimetabolites (such as methotrexate), mycotoxins in contaminated corn meal, arsenic, hyperthermia in early development, and radiation.[38][39][40] Maternal obesity has also been found to be a risk factor for NTDs.[41] Studies have shown that both maternal cigarette smoking and maternal exposure to secondhand smoke increased the risk for neural tube defects in offspring.[42] A mechanism by which maternal exposure to cigarette smoke could increase NTD risk in offspring is suggested by several studies that show an association between cigarette smoking and elevations of homocysteine levels.[43] Cigarette smoke during pregnancy, including secondhand exposure, can increase the risk of neural tube defects.[44] All of the above may act by interference with some aspect of normal folic acid metabolism and folate linked methylation related cellular processes as there are multiple genes of this type associated with neural tube defects.[45]

In addition to MTHFR variants, genetic polymorphisms in methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) can also influence NTDs risk by increasing the body's dependence on choline-derived methyl groups to compensate for impaired folate metabolism. One study found that premenopausal women with MTHFD1 variants were significantly more likely to experience organ dysfunction related to choline insufficient and had a heightened risk of NTDs in pregnancy.[33]

Other

[edit]

Folic acid supplementation reduces the prevalence of neural tube defects by approximately 70% of neural tube defects indicating that 30% are not folate-dependent and are due to some cause other than alterations of methylation patterns.[46] Multiple other genes related to neural tube defects exist which are candidates for folate insensitive neural tube defects.[45] There are also several syndromes such as Meckel syndrome, and triploid syndrome which are frequently accompanied by neural tube defects that are assumed to be unrelated to folate metabolism[47]

Diagnosis

[edit]

Tests for neural tube defects include ultrasound examination and measurement of maternal serum alpha-fetoprotein (MSAFP). Second trimester ultrasound is recommended as the primary screening tool for NTDs, and MSAFP as a secondary screening tool.[48] This is due to increased safety, increased sensitivity and decreased false positive rate of ultrasound as compared to MSAFP.[48] Amniotic fluid alpha-fetoprotein (AFAFP) and amniotic fluid acetylcholinesterase (AFAChE) tests are also used to confirming if ultrasound screening indicates a positive risk.[49] Often, these defects are apparent at birth, but acute defects may not be diagnosed until much later in life. An elevated MSAFP measured at 16–18 weeks gestation is a good predictor of open neural tube defects, however the test has a very high false positive rate, (2% of all women tested in Ontario, Canada between 1993 and 2000 tested positive without having an open neural tube defect, although 5% is the commonly quoted result worldwide) and only a portion of neural tube defects are detected by this screen test (73% in the same Ontario study).[50] MSAFP screening combined with routine ultrasonography has the best detection rate although detection by ultrasonography is dependent on operator training and the quality of the equipment.[51][52]

Prevention

[edit]

Incidence of neural tube defects has been shown to decline through maintenance of adequate folic acid levels prior to and during pregnancy. This is achieved through dietary sources and supplementation of folic acid.[53] In 1996, the United States Food and Drug Administration published regulations requiring the addition of folic acid to enriched breads, cereals, flour and other grain products.[54] Similar regulations made it mandatory to fortify selected grain products with folic acid in Canada by 1998.[55] During the first four weeks of pregnancy (when most women do not even realize that they are pregnant), adequate folate intake is essential for proper operation of the neurulation process. Therefore, any individuals who could become pregnant are advised to eat foods fortified with folic acid or take supplements in addition to eating folate-rich foods to reduce the risks of serious birth defects.[56][57][58] In Canada, mandatory fortification of selected foods with folic acid had been shown to reduce the incidence of neural tube defects by 46% compared to incidence prior to mandatory fortification.[59] However, relying on eating a folate-rich diet alone is not recommended for preventing neural tube defects when trying to conceive because a regular diet usually does not contain enough folate to reach pregnancy requirements.[60][61] All individuals who have the ability to become pregnant are advised to get 400 micrograms of folic acid daily.[62][63] This daily 400 mcg dose of folic acid can be found in most multivitamins advertised as for women.[64] Higher doses can be found in pre-natal multivitamins but those doses may not be necessary for everyone.[65][66] Individuals who have previously given birth to a child with a neural tube defect and are trying to conceive again may benefit from a supplement containing 4.0 mg daily, following advice provided by their doctor.[64] In Canada, guidelines on folic acid intake when trying to conceive is based on a risk assessment of how likely they are to experience a neural tube defect during pregnancy. Risk is divided into high, moderate, and low risk categories.[63] High risk would include those that had a past experience with neural tube defects, either themselves or during another pregnancy.[63] Medium risk individuals are those with certain conditions that put them at higher risk for experiencing a neural tube defect. These include having a first or second degree relative or partner with a history of neural tube defects, having a gastrointestinal condition that affects normal absorption patterns, advanced kidney disease, kidney dialysis, alcohol over-use, or had another pregnancy resulting in a congenital abnormality that was folate sensitive. Medium risk individuals would also include those taking medications that can interfere with folate absorption such as anticonvulsants, metformin, sulfasalazine, triamterene, and trimethoprim.[63] Low risk would include everyone else that do not fall into either medium or high risk categories. Recommendations on when to start folic acid supplementation for all individuals looking to become pregnant is at least three months preconception.[61][63] If an individual is in the high risk category, the recommended dose is 4–5 mg of folic acid daily until 12 weeks gestation and then decrease to 0.4–1 mg until 4–6 weeks postpartum or for however long breastfeeding lasts.[63] If an individual is in the medium risk category, the recommended dose is 1 mg of folic acid daily until 12 weeks gestation and then they can either continue at 1 mg or decrease to 0.4 mg daily until 4–6 weeks postpartum or however long breastfeeding lasts.[63] If the pregnancy is low risk to develop a neural tube defect then the recommendation for that individual is 0.4 mg daily until 4–6 weeks postpartum or however long breastfeeding lasts.[63] All dose recommendations and risk assessment should be done with the advice of a qualified health care provider.[62]

Treatment

[edit]

As of 2008, treatments of NTDs depends on the severity of the complication. No treatment is available for anencephaly and infants usually do not survive more than a few hours. Aggressive surgical management has improved survival and the functions of infants with spina bifida, meningoceles and mild myelomeningoceles.[67] The success of surgery often depends on the amount of brain tissue involved in the encephalocele. The goal of treatment for NTDs is to allow the individual to achieve the highest level of function, and independence. Fetal surgery in utero before 26 weeks gestation has been performed with some hope that there is benefit to the outcome including a reduction in Arnold–Chiari malformation and thereby decreases the need for a ventriculoperitoneal shunt but the procedure is very high risk for both mother and baby and is considered extremely invasive with questions that the positive outcomes may be due to ascertainment bias and not true benefit. Further, this surgery is not a cure for all problems associated with a neural tube defect. Other areas of research include tissue engineering and stem cell therapy but this research has not been used in humans.[68]

Epidemiology

[edit]
Deaths from neural tube defects per million persons in 2012
  0–0
  1–1
  2–3
  4–6
  7–10
  11–15
  16–20
  21–28
  29–69

Neural tube defects resulted in 71,000 deaths globally in 2010.[69] It is unclear how common the condition is in low income countries.[70]

Prevalence rates of NTDs at birth used to be a reliable measure for the actual number of children affected by the diseases.[71] However, due to advances in technology and the ability to diagnose prenatally, the rates at birth are no longer reliable.[71] Measuring the number of cases at birth may be the most practical way, but the most accurate way would be to include stillbirths and live-births.[71] Most studies that calculate prevalence rates only include data from live births and stillborn children and normally exclude the data from abortions and miscarriages.[71] Abortions are a huge contributing factor to the prevalence rates; one study found that in 1986 only a quarter of the pregnancies with an identified NTD were aborted, but that number had already doubled by 1999.[71] Through this data, it is clear that excluding data from abortions could greatly affect the prevalence rates. This could also possibly explain why prevalence rates have appeared to drop. If abortions are not being included in the data but half of the identified cases are being aborted, the data could show that prevalence rates are dropping when they actually are not. However, it is unclear how much of an impact these could have on prevalence rates due to the fact that abortion rates and advances in technology vary greatly by country.[71]

There are many maternal factors that also play a role in prevalence rates of NTDs.[71] These factors include things like maternal age and obesity all the way to things like socioeconomic status along with many others.[71] Maternal age has not been shown to have a huge impact on prevalence rates, but when there has been a relationship identified, older mothers along with very young mothers are at an increased risk.[71] While maternal age may not have a huge impact, mothers that have a body mass index greater than 29 double the risk of their child having an NTD.[71] Studies have also shown that mothers with three or more previous children show moderate risk for their next child having an NTD.[71]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Neural tube defect

View on Grokipedia
from Grokipedia
Neural tube defects (NTDs) are congenital malformations of the central nervous system caused by the failure of the neural tube to close completely during the third and fourth weeks of embryonic development, resulting in defects such as spina bifida, anencephaly, and encephalocele.[1] These conditions arise from disruptions in neurulation, the process forming the brain and spinal cord, and lead to a spectrum of outcomes ranging from fetal lethality in anencephaly to lifelong disabilities in spina bifida, including paralysis, hydrocephalus, and impaired bowel and bladder function.[1] Globally, NTDs affect an estimated 2 per 1,000 births, equating to 214,000–322,000 cases annually, with higher prevalence in regions lacking folic acid fortification or supplementation programs.[2] Etiologically multifactorial, NTDs involve genetic susceptibilities—accounting for 60–70% of risk—and environmental factors, prominently maternal folate insufficiency during periconception, which randomized trials show can be mitigated by daily folic acid intake of 400 μg, reducing occurrence by up to 71%.[3][4] Public health interventions, including mandatory grain fortification, have halved rates in implemented countries, underscoring folate's causal role while highlighting persistent genetic and unidentified contributors.[5]

Definition and Embryology

Neural Tube Formation Process

The formation of the neural tube, known as primary neurulation, commences during the third week of human embryonic development, approximately 18-20 days post-fertilization, when the neural plate emerges as a thickened region of the dorsal ectoderm induced by underlying notochordal signals.[6] This plate undergoes mediolateral narrowing and anteroposterior elongation via convergent extension, a process conserved across vertebrates and observed in histological sections of human embryos staged at Carnegie stages 7-8.[7] The neural plate's central region then invaginates, forming a longitudinal neural groove bounded by paired neural folds, driven primarily by apical constriction of neuroepithelial cells where actomyosin contractility reshapes the epithelium into a pseudostratified configuration.[8][7] Neural fold elevation follows, occurring through a combination of cellular wedging at the hinge points—where basal nuclei migration and microtubule-mediated bending occur—and purse-string contraction of actin-myosin cables along the fold apices, as evidenced by time-lapse imaging in chick and mouse models that mirror human dynamics.[7] The folds progressively approximate midline-ward, with zippering fusion initiating at the hindbrain-cervical junction around embryonic day 22-23, progressing bidirectionally: the anterior (cranial) neuropore closes by day 25, and the posterior (caudal) neuropore by day 27-28 post-fertilization, completing the tube's enclosure before the embryo reaches 4-5 mm in length.[9][6] This temporal window, confirmed by serial sectioning of human embryos archived in collections like the Kyoto Collection, underscores the process's rapidity, with disruptions post-day 28 yielding secondary rather than primary defects.[6] Fusion at the midline involves selective apoptosis of nascent neural crest cells and epithelial remnants, generating localized force to eliminate bridging tissues and ensure seamless apposition without persistent perforations, as demonstrated in avian models where inhibiting caspases delays closure.[10] Histological evidence from mammalian embryos reveals programmed cell death peaks precisely at fusion sites, facilitating dorsal midline remodeling while preserving tube integrity, a mechanism evolutionarily conserved from amphibians to humans.[11] These cellular events—invagination, elevation, fusion, and apoptotic refinement—collectively transform the flat neural plate into a closed cylindrical structure housing future central nervous system progenitors, reliant on coordinated cytoskeletal dynamics and extracellular matrix remodeling.[7]

Pathophysiological Mechanisms of Closure Failure

Neural tube closure requires precise coordination of cellular behaviors, including apical constriction, convergent extension, and fusion of neural folds, any disruption of which can result in non-closure.[7] In vertebrates, failure often manifests as multifocal breakdowns, with empirical evidence from live imaging in mouse and Xenopus embryos revealing defects at independent sites such as the anterior neuropore, caudal neuropore, and posterior neuropore.[12] These proximal mechanisms involve imbalances in neuroepithelial cell proliferation, migration, and differentiation, leading to insufficient tissue mass or malformed folds that prevent apposition and sealing.[7] Human autopsy studies corroborate this, showing non-fused neural folds with disrupted epithelial integrity at closure sites, though direct causation remains inferred from animal models due to ethical limits on embryonic sampling.[13] At the cellular level, disrupted cytoskeletal dynamics impair neural fold elevation and convergence. Actomyosin contractility, driven by pulsatile actin-myosin interactions, generates wedge-shaped neuroepithelial cells via apical constriction at median and dorsolateral hinge points; failures in actin turnover or disassembly result in flattened cells unable to bend the neural plate effectively, as observed in disrupted mouse spinal closures.[7] Planar cell polarity defects further exacerbate this by hindering convergent extension, a process reliant on oriented cell intercalation and migration, yielding a widened neural plate that resists midline convergence, verifiable through time-lapse imaging of vertebrate embryos.[12] Collective cell movement falters without these polarities, with reduced filopodial or lamellipodial protrusions at fold tips preventing adhesion and zippering during fusion.[7] Apoptosis contributes to shaping the closing tube by eliminating superfluous cells at hinge regions and boundaries, generating localized force for bending, as demonstrated in chick embryo imaging where inhibition blocks median hinge point formation and closure.[12] However, excessive or disorganized cell death depletes the neuroepithelium, reducing proliferative capacity and exacerbating migration deficits, with vertebrate models showing elevated apoptotic rates preceding or concurrent with failed apposition.[13] In mammalian systems, while basal apoptosis is not strictly essential for closure, dysregulation—evidenced by knockout-induced imbalances—leads to inefficient tissue remodeling and persistent open defects.[7] Biomechanically, closure failure arises from unresolved force tensions across the ectoderm-neuroepithelium interface, where imbalanced proliferation (e.g., faster non-neural ectoderm growth) stretches the plate, opposing elevation, as quantified in mouse embryo tension assays.[7] Fusion requires counterbalanced intrinsic (contractile) and extrinsic (mesenchymal) forces for fold apposition; deficits manifest as stalled zippering, with multifocal imaging in models confirming site-specific vulnerabilities rather than a singular global defect.[12] These mechanisms underscore a multifactorial cascade, where proximal cellular lapses amplify into tissue-level non-closure without invoking secondary rupture, though the latter remains a debated alternative in select cases.[13]

Classification and Types

Open Neural Tube Defects

Open neural tube defects arise from failure of primary neurulation, resulting in incomplete closure of the neural tube and exposure of neural tissue to the amniotic cavity or postnatal environment.[14] This exposure manifests as direct protrusion of unfused neural placodes, meninges, and cerebrospinal fluid (CSF) leakage through vertebral or cranial gaps, as seen in myelomeningocele where spinal neural elements herniate sac-like beyond the skin.[15] Unlike closed defects, the absence of dermal covering leaves neural structures vulnerable to mechanical disruption, osmotic imbalance from amniotic fluid constituents, and microbial invasion, initiating cascades of secondary neurodegeneration.[16] The pathophysiological hallmark of open defects is the persistence of an open dysraphic site, permitting bidirectional fluid exchange that erodes viable neural epithelium over time.[17] Amniotic fluid toxicity, evidenced by neuroepithelial cell damage in exposed defects, compounds primary closure failure by inducing inflammation and apoptosis in the placode.[18] Postnatally, this configuration heightens risks of ascending infections, with cohort analyses linking delayed repair to elevated incidences of CSF leaks, wound dehiscence, and ventriculitis.[19] Empirical data from surgical series underscore the morbidity gradient: open defects exhibit infection rates tied to exposure duration, where unrepaired myelomeningoceles foster bacterial colonization from cutaneous or amniotic sources, amplifying tissue destruction beyond the initial malformation.[20] Such vulnerabilities necessitate causal prioritization of barrier restoration to mitigate trauma-induced gliosis and hydrocephalus precursors, as prolonged openness correlates with poorer neural preservation in observational cohorts.[21] This exposure-driven pathology differentiates open neural tube defects mechanistically, demanding interventions that address both the defect and its sequelae promptly.[22]

Closed Neural Tube Defects

Closed neural tube defects, also termed closed spinal dysraphisms, involve malformations of the spinal column's bone, fat, or membranes that remain covered by intact skin, distinguishing them from open defects by the absence of exposed neural elements.[23] These conditions arise from disruptions in secondary neurulation, resulting in structural anomalies without overt neural placode exposure.[14] Unlike open variants, closed defects often present with minimal or no immediate symptoms at birth, but they carry risks of progressive neurological compromise due to mechanical factors such as spinal cord tethering.[24] The prototypical example is spina bifida occulta, characterized by a focal vertebral arch defect in the lumbosacral region, with the spinal cord or its coverings adherent to overlying tissues beneath unbroken skin.[25] Cutaneous stigmata, such as dermal sinuses, tufts of hair, subcutaneous lipomas, or hemangiomas, may overlie the site in up to 80% of cases, serving as clinical clues, though many individuals remain asymptomatic throughout life.[26] Prevalence of spina bifida occulta reaches 10-20% in the general population based on radiographic surveys, yet symptomatic manifestations occur in only about 1 in 1,000 affected individuals, typically emerging during periods of rapid spinal growth like adolescence.[27] [28] A primary chronic risk stems from tethered cord syndrome, where inelastic attachments restrict spinal cord mobility, inducing tensile forces that exacerbate ischemia, gliosis, and neuronal dysfunction over time.[29] This can manifest as subtle motor weakness, sensory alterations, gait instability, or neurogenic bladder dysfunction, with empirical studies documenting progressive deterioration in untreated cases, including up to 40% exhibiting a triad of pain, weakness, and urinary symptoms at presentation.[30] [31] Despite reduced overt severity compared to open defects—evidenced by lower rates of immediate paraplegia or hydrocephalus—longitudinal data reveal cumulative morbidity from orthopedic deformities like scoliosis and urological complications, underscoring the need for vigilant monitoring.[32] Diagnosis hinges on imaging due to the concealed nature of these dysraphisms; plain radiographs may detect vertebral anomalies, but magnetic resonance imaging is essential to delineate cord tethering or intradural anomalies, as superficial signs alone underestimate underlying pathology in over half of cases.[33] This subtlety challenges early identification, with many cases incidental until adulthood, when degenerative changes amplify symptoms.[34]

Specific Variants (Anencephaly, Encephalocele, Iniencephaly, Hydranencephaly, Spina Bifida)

Anencephaly is characterized by the absence of the cranial vault (calvarium) and cerebral hemispheres, with only the brainstem and basal structures typically preserved, resulting in a frog-like facial appearance due to exposed orbital contents and lack of forebrain development.[35] This severe defect leads to immediate postnatal lethality, with survival rarely exceeding one week due to the inability to maintain vital functions.[36] Prenatal diagnosis via ultrasound reveals the hallmark "anencephaly sign," including absent cranial bones and a flattened skull base, with an incidence of approximately 1 per 1,000 births globally.[35] Encephalocele involves the herniation of meninges, cerebrospinal fluid, and often neural tissue through a midline skull defect, most commonly occipital (75-80% of cases) but also frontal or parietal, forming a sac-like protrusion covered by skin or thin membrane.[37] The herniated contents may include malformed brain tissue, leading to variable neurological impairment depending on the volume and location of protrusion.[37] Diagnostic ultrasound shows the characteristic sac extending from the cranium, with an incidence of about 1 per 10,000 live births in the United States.[1] Iniencephaly features extreme retroflexion of the head with fusion of the occiput to the cervical spine, resulting in a short or absent neck, thoracic lordosis, and often rachischisis (open spinal defect) of the upper spine.[38] The craniovertebral junction shows defective closure with retroverted atlas and axis vertebrae, rendering the condition uniformly lethal shortly after birth due to respiratory and brainstem compromise.[39] It occurs at a rarity of 0.1 to 10 per 10,000 pregnancies, predominantly in females.[38] Hydranencephaly presents as near-total absence of the cerebral hemispheres, replaced by fluid-filled sacs, while the falx cerebri, brainstem, cerebellum, and basal ganglia remain intact, distinguishing it from primary neural tube closure failures by its destructive etiology often involving vascular occlusion.[40] Diagnostic imaging, such as prenatal ultrasound or postnatal MRI, reveals echolucent supratentorial structures with preserved midline and posterior fossa elements, mimicking severe hydrocephalus but without ventricular expansion.[40] Though rare, with incidence estimates under 1 per 10,000 births, it leads to profound developmental arrest and early mortality.[40] Spina bifida encompasses a spectrum of defects in vertebral arch closure, ranging from occult (asymptomatic, skin-covered) to myelomeningocele (open defect with neural placode protrusion in a meningeal sac), primarily affecting the lumbosacral region and causing variable lower limb paralysis, bladder dysfunction, and hydrocephalus.[41] Prenatal ultrasound identifies the "lemon sign" (scalloped frontal bones) and "banana sign" (curved cerebellum) as indirect markers, with direct visualization of the spinal defect confirming diagnosis.[41] Prior to widespread folic acid fortification in the 1990s, incidence reached approximately 1 per 1,000 births in affected populations.[42]

Etiology

Genetic Factors and Heritability

Neural tube defects (NTDs) exhibit substantial heritability, with genetic factors estimated to account for approximately 60-70% of the variance in susceptibility based on twin studies and segregation analyses.[43][44] This polygenic architecture involves multiple loci of small effect, alongside rarer structural variants, underscoring a predominantly genetic basis rather than sporadic environmental triggers alone.[45] Familial aggregation is evident, with recurrence risks for siblings of affected individuals ranging from 2-5%, representing a 20-50-fold increase over population baselines of about 0.1%.[46] Consanguinity further elevates this risk by increasing homozygosity for recessive alleles, with studies in high-consanguinity populations reporting odds ratios up to 2-3 times higher for NTDs compared to non-consanguineous matings.[47][48] Candidate gene studies have implicated variants in folate metabolism pathways, notably polymorphisms in MTHFR (e.g., C677T), which impair homocysteine remethylation and are associated with elevated NTD risk in meta-analyses (odds ratios 1.2-1.5).[43] Similarly, mutations in planar cell polarity genes like VANGL1 and VANGL2 disrupt convergent extension during neural tube closure, with rare missense variants (e.g., V239I, R274Q in VANGL1) identified in 1-2% of familial and sporadic cases.[49][50] Genome-wide association studies (GWAS) have confirmed polygenic contributions, identifying loci near genes involved in ciliogenesis and sonic hedgehog signaling, though effect sizes remain modest (e.g., top SNPs with p < 10^{-5}).[51] Recent optical genome mapping analyses reveal structural variants, including copy number variants, in 8-13% of NTD cases, often affecting VANGL-related or apoptosis pathway genes validated in mouse models.[52] These findings highlight de novo and inherited variants as contributors beyond common polymorphisms, with diagnostic yields improving via high-resolution sequencing.[45]

Environmental and Nutritional Risk Factors

Low maternal folate status prior to and during early pregnancy is a well-established nutritional risk factor for neural tube defects (NTDs), with meta-analyses indicating odds ratios of approximately 1.5 to 3.0 for low serum or red blood cell folate levels compared to sufficient levels.[53] Periconceptional folic acid supplementation reduces NTD risk by 50-70% in randomized trials and population studies, but does not eliminate it entirely, as residual cases persist even with adequate intake, underscoring multifactorial etiology beyond folate alone.[54] Prior to widespread awareness and fortification programs in the 1990s, folate insufficiency contributed to higher NTD prevalence, with birth rates exceeding 1 per 1,000 in many regions lacking supplementation.[55] Maternal pregestational diabetes significantly elevates NTD risk through mechanisms involving hyperglycemia-induced oxidative stress and disrupted embryonic folate metabolism, with relative risks ranging from 2 to 10 fold in cohort studies, depending on glycemic control.[56] This association holds independently of folate status in some analyses, though optimal diabetes management and folate supplementation may mitigate but not fully prevent the excess risk.[57] Anticonvulsant medications, particularly valproic acid, pose a prominent environmental teratogenic risk, with meta-analyses of exposed pregnancies reporting adjusted odds ratios of 9.7 to 20.6 for NTDs, especially spina bifida, compared to unexposed controls.[58] [59] This elevated risk persists across dosages but is dose-dependent, prompting guidelines to avoid valproate in women of childbearing potential unless alternatives are infeasible.[60] Other potential contributors, such as maternal obesity (OR ~1.5-2.0) and hyperthermia from fever or hot tub use, show associative evidence from case-control studies but require further causal validation.[61]

Gene-Environment Interactions and Multifactorial Causation

Neural tube defects (NTDs) are understood to arise through multifactorial inheritance, where genetic susceptibility interacts with environmental exposures to exceed a liability threshold, resulting in failure of neural tube closure. Under this model, multiple low-penetrance genetic variants contribute to an underlying liability distributed normally in the population, with affected individuals representing those whose total liability surpasses a developmental threshold; environmental factors modulate this risk by altering the threshold position or liability load, explaining the observed familial aggregation without mendelian patterns.[62][63][64] A prominent gene-environment interaction involves variants in the MTHFR gene, which encodes methylenetetrahydrofolate reductase, an enzyme critical for folate metabolism. The maternal C677T polymorphism in MTHFR reduces enzyme activity, elevating homocysteine levels and impairing folate utilization, thereby increasing NTD risk particularly in contexts of suboptimal maternal folate intake; periconceptional folic acid supplementation normalizes folate status and mitigates this risk even in homozygous TT carriers, underscoring how environmental folate availability interacts with genetic predisposition to prevent or precipitate defects.[65][66] Similar interactions occur with other folate pathway genes, where low maternal folate synergizes with polymorphisms to heighten susceptibility, as evidenced by family-based association studies showing gene-folate effects on NTD occurrence.[67] Epigenetic mechanisms further illustrate these interactions, with folate deficiency disrupting DNA methylation and histone modifications essential for neural tube gene regulation. Recent analyses indicate that folate shortfall reduces DOT1L-mediated histone H3K79 methylation, leading to aberrant gene expression in neurulation pathways, while post-translational histone alterations in NTD tissues correlate with environmental insults like maternal nutrient deficits; these changes, potentially reversible by folate repletion, highlight how environmental factors epigenetically amplify genetic vulnerabilities during the brief window of tube closure.[68][69][70] Maternal history of spontaneous abortion or younger age (<20 years) elevates NTD risk through interactions potentially involving cumulative environmental exposures or altered folate homeostasis, with odds ratios indicating 2- to 10-fold increases in affected cohorts; these factors likely intersect with genetic liability, as prior reproductive losses may reflect unresolved metabolic stressors that compound periconceptional risks in susceptible genotypes.[71][72][73] Additional triggers, such as exposure to polycyclic aromatic hydrocarbons or arsenic in genetically predisposed individuals, similarly demonstrate multifactorial causation, emphasizing empirical complexity over singular attributions.[74][75]

Epidemiology

Global and Regional Prevalence

The global prevalence of neural tube defects (NTDs), encompassing conditions such as anencephaly and spina bifida, is estimated at 18.6 per 10,000 live births.[76] This equates to approximately 260,100 NTD-affected birth outcomes worldwide in 2015, excluding early spontaneous losses.[77] Prevalence varies substantially by region, with higher rates reported in low-resource areas lacking widespread folic acid fortification of food supplies.[78] In sub-Saharan Africa, NTD prevalence averages 69.8 per 10,000 births, with some areas reaching 98.2 per 10,000.[79] Eastern Africa exhibits rates up to five times those in fortified Western nations.[80] Across Asia, Southern and East Asia bear a disproportionate per capita burden, contributing significantly to global cases.[81] In contrast, regions with mandatory fortification programs, such as North America and Europe, report lower averages, ranging from 1.3 to 35.9 per 10,000 births in Europe and 3.3 to 27.9 per 10,000 in the Americas.[78] Ethnic disparities are evident within populations; in the United States, Hispanic women experience the highest rates of spina bifida-affected births at approximately 1 in 1,705 live births, exceeding rates among non-Hispanic white and black women.[82] These variations underscore geographic and demographic differences in NTD occurrence, independent of temporal changes.[83]

Temporal Trends and Influences

The incidence of neural tube defects (NTDs) exhibited peaks in many regions prior to the 1990s, with rates such as 8 per 10,000 live births for anencephaly in the United States during the 1970s, reflecting higher baseline prevalence influenced by nutritional and environmental factors.[84] Declines began in the late 20th century even before widespread interventions, as evidenced by U.S. data showing reductions to 3-4 per 10,000 for anencephaly by the 1980s, attributable in part to improvements in maternal nutrition and prenatal care unrelated to targeted fortification.[84] [85] Mandatory folic acid fortification of food supplies, implemented in countries like the United States in 1998 and Canada in 1998, correlated with accelerated reductions in NTD prevalence, including a 19% drop in U.S. birth prevalence post-fortification and significant decreases in Canada, empirically linking temporal patterns to increased population-level folate intake.[86] [87] Globally, NTD incidence, mortality, and disability-adjusted life years (DALYs) showed favorable downtrends from 1990 to 2019, with fortification programs in multiple nations contributing to non-uniform but substantial declines exceeding 20-50% in fortified regions.[88] [89] However, these reductions were non-linear, as pre-fortification downward trajectories in some areas suggest multifactorial causation, including socioeconomic advancements and voluntary supplementation, rather than fortification alone accounting for all variance.[85] In recent decades, declines have stalled or reversed in select populations despite ongoing fortification, indicating persistent influences beyond folate status, such as genetic predispositions or residual environmental risks. For instance, in urban China (Haidian District, Beijing), NTD prevalence among 363,732 births from 2013 to 2022 initially decreased but then stabilized around 8.14 per 10,000 after fluctuating increases, showing no overall significant change.[90] Similarly, spina bifida rates in England exhibited a slow annual increase of approximately 1% from 2000 to 2019, predating and persisting amid fortification efforts.[91] These patterns underscore that while folic acid fortification empirically drove post-1990s reductions, incomplete prevention and regional stalls highlight limits in causal attribution, with data from surveillance systems like those from the CDC and Global Burden of Disease studies emphasizing the need for ongoing monitoring of non-folate factors.[92] [89]

Demographic Risk Profiles

Neural tube defects (NTDs) exhibit elevated prevalence among cohorts with younger maternal age, particularly under 25 years, as evidenced by a case-control study in Ethiopia's Tigray region where mothers aged ≤25 years had an adjusted odds ratio (AOR) of 6.585 (95% CI: 1.799–24.101) for NTD-affected births compared to older groups.[73] This association reflects inherent biological vulnerabilities in early reproductive years, compounded by modifiable factors such as delayed family planning or limited preconception care access. While some population studies describe a U-shaped risk curve with peaks at both younger and advanced maternal ages, cohort data from low-resource settings consistently highlight disproportionate burden among adolescents and young adults.[93] Low maternal education emerges as a robust predictor of NTD risk across diverse cohorts, likely mediating through modifiable pathways like reduced awareness of folic acid supplementation and poorer nutritional intake. In a Colorado population-based study (1989–1998), mothers with less than a 10th-grade education faced an adjusted odds ratio of 1.8 (95% CI: 1.1–3.1) for NTD-affected pregnancies.[94] Similarly, in the Tigray cohort, no formal education conferred an AOR of 20.846 (95% CI: 2.265–191.856), with risks diminishing but persisting across elementary and high school levels (AORs 14.365 and 13.801, respectively).[73] These gradients underscore socioeconomic disparities, where low education correlates with inherent rural residence and low SES but is amenable to interventions enhancing health literacy. Prior pregnancy losses, including abortions and stillbirths, correlate with heightened NTD risk in subsequent gestations, potentially signaling underlying modifiable maternal health deficits or inherent genetic susceptibilities. The Tigray study reported an AOR of 2.516 (95% CI: 0.990–6.397) for mothers with such history, though borderline significance (p=0.053) suggests confounding by nutritional status.[73] Cohort analyses further indicate that immediate prior spontaneous abortions elevate NTD odds, independent of recurrence from prior NTDs.[95] In siege-affected Tigray (2020–2022 conflict), these obstetric risks amplified amid food insecurity (58.4% limited to ≤2 meals/day) and healthcare disruptions (91.9% access denial), illustrating how acute stressors exacerbate demographic vulnerabilities in low-SES groups.[73]

Diagnosis and Screening

Prenatal Diagnostic Methods

Prenatal diagnosis of neural tube defects (NTDs) primarily relies on non-invasive screening via maternal serum alpha-fetoprotein (MS-AFP) testing and fetal ultrasound, with invasive procedures like amniocentesis used for confirmation when indicated.[96][97] MS-AFP screening measures alpha-fetoprotein levels in maternal blood, which are elevated in pregnancies affected by open NTDs due to leakage of fetal serum proteins into the amniotic fluid and maternal circulation.03883-1/fulltext) This test is optimally performed between 16 and 18 weeks of gestation, as AFP peaks around this period and provides the highest detection sensitivity.92549-1/fulltext)[98] MS-AFP detects approximately 85% of open NTDs, such as anencephaly and open spina bifida, though false positives can occur due to factors like inaccurate gestational dating, multiple gestations, or fetal demise.03883-1/fulltext)[99] Elevated levels prompt further evaluation, but normal MS-AFP does not rule out closed NTDs or skin-covered defects.[96] In regions with routine folic acid fortification, MS-AFP utility has diminished somewhat, but it remains a standard second-trimester screen integrated into quadruple or combined tests for aneuploidy and NTDs.[96] Fetal ultrasound serves as the cornerstone for detailed anatomic assessment and definitive prenatal diagnosis of NTDs, offering visualization of spinal and cranial structures with detection rates exceeding 95% when performed by experienced operators.[100] The routine anomaly scan, typically conducted at 18 to 22 weeks gestation, evaluates for signs such as the "lemon" sign (scalloped frontal bones in anencephaly), "banana" sign (cerebellar Arnold-Chiari malformation in spina bifida), or absent cranial vault.[101] Earlier transvaginal ultrasound around 11 to 14 weeks can identify some NTDs, including increased nuchal translucency or cranial defects, though resolution limits detection of subtle spinal lesions.[102] High-resolution 3D ultrasound or targeted neurosonography enhances specificity for complex cases, reducing the need for invasive testing.[103] If non-invasive screening suggests an NTD, amniocentesis between 15 and 20 weeks provides confirmatory amniotic fluid AFP and acetylcholinesterase levels, with elevated amniotic AFP indicating an open defect and acetylcholinesterase confirming neural tissue exposure.[104][105] This invasive test carries a small risk of miscarriage (approximately 0.1-0.3%) but offers high diagnostic accuracy, often combined with genetic analysis to exclude associated chromosomal anomalies.[97] Overall, advancements in ultrasound have shifted emphasis from biochemical markers alone, improving early detection while minimizing risks.[96][106]

Postnatal Identification and Confirmation

Neural tube defects (NTDs) are frequently identified at birth via physical examination, which reveals overt structural anomalies in the spine or cranium. For open spina bifida, particularly myelomeningocele, a key postnatal sign is a midline lumbosacral sac protruding through a vertebral defect, containing neural tissue, meninges, and cerebrospinal fluid, typically lacking skin coverage.[107] [41] Accompanying features include lower extremity weakness or paralysis, absent deep tendon reflexes below the lesion level, and impaired perineal sensation or anal tone, indicating neural involvement.[108] Confirmation of the defect's extent and associated anomalies requires imaging studies. Plain X-rays delineate the skeletal vertebral gaps and any scoliosis or kyphosis, while spinal ultrasound assesses soft tissue and cord tethering in neonates.[109] Magnetic resonance imaging (MRI) provides detailed visualization of neural elements, thecal sac integrity, Chiari II malformation, and hydrocephalus, guiding surgical planning.[41] [109] In encephalocele, postnatal inspection shows a scalp or skull-based mass with brain herniation, confirmed by MRI to evaluate contents and intracranial connections. Anencephaly, being incompatible with life, manifests as acrania with exencephaly, requiring minimal confirmatory imaging beyond clinical observation.[41] Closed defects like spina bifida occulta may evade initial detection, necessitating MRI if subtle signs such as dermal sinuses or tufts of hair prompt suspicion.[28]

Prevention Strategies

Folic Acid Supplementation and Fortification

Periconceptional folic acid supplementation has been established as an effective preventive measure against neural tube defects (NTDs) through randomized controlled trials. The Medical Research Council (MRC) Vitamin Study, a multicenter double-blind trial conducted from 1985 to 1991 involving 1817 women with a previous NTD-affected pregnancy, found that daily intake of 4 mg folic acid starting one month before conception and continuing through the first two months of pregnancy reduced NTD recurrence by 72%, with an incidence of 1.0% in the folic acid group versus 3.5% in the placebo group and 4.0% in the multivitamin group lacking folic acid.[110][111] This high-dose regimen proved superior to other vitamins or placebo, supporting targeted supplementation for high-risk women planning pregnancy.[112] For primary prevention of first-occurrence NTDs, a Hungarian randomized trial published in 1992 demonstrated that periconceptional multivitamin supplementation containing 0.8 mg folic acid reduced NTD incidence by about 73% compared to a trace vitamin regimen without folic acid, with rates of 2.0 per 1000 births in the folic acid group versus 7.3 per 1000 in the control group among 4751 women.[112] Subsequent evidence indicates that lower doses, such as 0.4 mg daily, are also efficacious for the general population, preventing up to 50-70% of NTDs when taken by women capable of becoming pregnant, as corroborated by meta-analyses of observational and trial data.[113][114] These findings underpin public health recommendations for routine 400 mcg folic acid intake from at least one month preconception through the first trimester, though adherence remains suboptimal without targeted education.[115] Mandatory folic acid fortification of staple foods has further reduced NTD prevalence at the population level by ensuring broad exposure without relying on individual compliance. In the United States, fortification of enriched cereal grains initiated in 1998 correlated with a 28% decline in NTD rates from 1995-2000, alongside elevated serum folate levels across demographics.[114] Similar outcomes occurred in Canada post-1998 fortification, with a 46% NTD reduction, and in Chile after 2000 wheat flour fortification at 220 µg/100 g, yielding a 43% drop from 17.1 to 9.7 per 10,000 births.[116] Global analyses confirm fortification's role in averting 20-50% of NTDs in implementing regions, though efficacy varies by baseline prevalence, fortification levels, and non-response in subgroups like obese women or those with certain genetic variants affecting folate metabolism.[117][118] Despite these gains, not all countries mandate fortification, contributing to persistent disparities in NTD burden.[119]

Lifestyle and Maternal Health Interventions

Maternal obesity prior to pregnancy is associated with an elevated risk of neural tube defects (NTDs) in offspring, with meta-analyses indicating approximately a twofold increase compared to women with normal body mass index (BMI 18.5–24.9 kg/m²).[120][121] Pre-pregnancy weight management through sustained lifestyle modifications, such as caloric restriction and increased physical activity, can mitigate this risk by normalizing BMI before conception, though direct randomized trials linking such interventions to reduced NTD incidence remain limited.[122] Maternal pregestational diabetes substantially heightens NTD risk, with relative risks ranging from 2.0 to 3.7 depending on diabetes type and control status.[123][124] Effective glycemic control via preconception insulin optimization, dietary adjustments, and exercise reduces hyperglycemia-induced embryopathy, potentially lowering NTD occurrence, as evidenced by observational data showing dose-dependent risk elevation with poor control.[57] Early and comprehensive prenatal care facilitates timely screening for obesity and diabetes, enabling interventions like supervised weight monitoring and metabolic management, which correlate with improved perinatal outcomes including reduced congenital anomaly rates.[125] However, while these measures address modifiable risk factors, their isolated impact on NTD prevention is confounded by interactions with genetic and nutritional elements, underscoring the need for integrated approaches rather than reliance on lifestyle alone.[126]

Genetic Counseling and Screening Limitations

Genetic counseling for neural tube defects (NTDs) primarily informs families of empirical recurrence risks based on family history, as NTDs exhibit multifactorial inheritance patterns with estimated heritability of 60-70%.[127] For siblings of an affected individual, the recurrence risk is approximately 2-5%, with studies reporting rates of 3.0% (95% CI 2.0-4.3%) in U.S. populations and 3.4% in clinic-based cohorts.[128] [129] These figures exceed general population incidence (around 0.1%) but remain low, reflecting the interplay of multiple genetic and non-genetic factors rather than Mendelian dominance.[130] The polygenic or oligogenic architecture of NTDs severely limits predictive accuracy in counseling, as over 200 genes implicated in mouse models have yielded few validated human causal variants despite extensive candidate gene and genome-wide association studies.[46] [131] No single-gene mutations account for the majority of cases, and sporadic occurrences predominate, complicating risk stratification beyond broad empirical data.[132] This complexity precludes routine genetic testing for presymptomatic identification of at-risk individuals, as polygenic risk scores remain underdeveloped and insufficiently validated for clinical use in NTDs.[133] Screening modalities integrated into counseling, such as maternal serum alpha-fetoprotein (AFP) testing, detect open NTDs with sensitivity around 80-90% but falter for closed defects like occult spinal dysraphism and yield false positives from unrelated factors, necessitating confirmatory imaging.[99] Invasive diagnostics like amniocentesis carry miscarriage risks (0.1-0.5%) and do not resolve underlying genetic heterogeneity.[134] Overall, these tools provide probabilistic rather than deterministic guidance, underscoring the challenge of translating heritability estimates into actionable, individualized advice amid unresolved gene-environment interactions.[43]

Management and Treatment

Surgical Interventions

Surgical interventions for neural tube defects primarily target myelomeningocele, the most common and surgically amenable form of open spina bifida, aiming to close the spinal defect to protect neural tissue from mechanical trauma, cerebrospinal fluid leakage, and infection.[135] For anencephaly, a lethal defect lacking cerebral hemispheres, no reparative surgery is feasible, as interventions cannot restore viable brain function.[16] Encephalocele repair, involving excision of herniated brain tissue and dural closure, is typically postnatal but less emphasized in neural tube defect literature compared to myelomeningocele.[136] Postnatal surgical closure remains the standard approach for myelomeningocele, performed within 24 to 48 hours of birth to minimize risks of meningitis and ascending neural damage.[137] Techniques involve multilayer reconstruction: the exposed neural placode is covered with autologous fascia or dura to achieve a watertight seal, followed by paraspinal muscle mobilization and skin flap closure, often requiring ventriculoperitoneal shunting for associated hydrocephalus in up to 80-90% of cases.[138] Outcomes include survival rates exceeding 90% in resource-equipped settings, but persistent challenges such as shunt dependence, tethered cord syndrome, and motor deficits below the lesion level, with functional ambulation achieved in only 20-30% of thoracic-level cases without orthotic support.[139] Fetal surgery for myelomeningocele, introduced to mitigate ongoing intrauterine damage from amniotic fluid exposure and the "two-hit hypothesis" of secondary injury, involves open hysterotomy between 19 and 26 weeks gestation for direct defect closure using similar multilayer techniques adapted for the fetus.[135] The Management of Myelomeningocele Study (MOMS), a multicenter randomized controlled trial enrolling 183 eligible pregnancies from 2003 to 2010, demonstrated that prenatal repair reduced ventriculoperitoneal shunt placement or full criteria met at 12 months by 50% (relative risk 0.70; 95% CI 0.58-0.85) and improved composite motor function scores at 30 months, with 42% of prenatal cases achieving independent walking versus 21% in postnatal controls.[140] However, fetal surgery increased risks of preterm delivery (mean 34.1 weeks vs. 37.1 weeks; P<0.001), oligohydramnios, and maternal complications including uterine dehiscence (10%) and need for hysterectomy (2%).[135] Long-term follow-up confirms sustained benefits in shunt independence and leg strength but highlights higher rates of maternal-fetal morbidity, restricting its use to centers with expertise and strict eligibility (e.g., lumbar lesions, no severe kyphosis).[141] Emerging minimally invasive fetoscopic approaches aim to replicate open repair benefits with reduced maternal risk via endoscopic skin-muscle-dura layering, but preliminary data show higher cerebrospinal fluid leak rates and no superiority in shunt reduction over postnatal methods in non-randomized cohorts.[142] Overall, while postnatal closure prioritizes immediate postnatal stability, fetal intervention's evidence from the MOMS RCT supports selective application for optimizing neurologic preservation, though broader adoption is limited by procedural complexity and risks unsupported by additional large-scale trials.[143]

Multidisciplinary Support and Rehabilitation

Individuals with spina bifida, the most common survivable neural tube defect, require coordinated care from multidisciplinary teams comprising neurosurgeons, orthopedic surgeons, physiatrists, physical and occupational therapists, psychologists, and educators to optimize motor function, independence, and psychosocial adjustment.[144][145] These teams address the variable impacts of spinal cord lesion levels, which determine paralysis extent, sensory loss, and secondary complications like scoliosis or contractures.[146] Orthopedic interventions emphasize mobility enhancement through custom orthoses, including ankle-foot orthoses (AFOs), knee-ankle-foot orthoses (KAFOs), and reciprocating gait orthoses (RGOs) for ambulatory support in lower-level lesions, alongside wheelchairs for higher lesions to promote household ambulation or community independence.[147][148] Physical therapy integrates casting, splinting, and strengthening exercises to maintain alignment, prevent deformities, and support weight-bearing activities, with monitoring for skin integrity to avoid pressure ulcers.[147] Surgical corrections for progressive scoliosis or hip dislocations may be necessary in up to 50-80% of cases depending on lesion level, aiming to preserve seating posture and pulmonary function.[145] Neurological rehabilitation targets residual motor and sensory deficits via targeted physical and occupational therapy protocols, focusing on gait training, balance, and upper extremity function to mitigate atrophy and enhance adaptive skills.[144] For associated hydrocephalus, often present in 80-90% of myelomeningocele cases, ventriculoperitoneal shunt management integrates with rehab to control intracranial pressure and support cognitive-motor integration, though shunt malfunctions necessitate vigilant multidisciplinary oversight.[145] Psychological support addresses elevated risks of depressive symptoms, linked to fewer positive peer and school contexts, through individual therapy and family counseling to foster resilience and intrinsic motivation.[149] Educational outcomes reveal challenges including lower IQ averages (often 70-85 range due to hydrocephalus), attention deficits, and executive function impairments, necessitating individualized education programs (IEPs) with accommodations for mobility, fatigue, and learning processing delays.[150] Studies indicate higher parental dependence and reduced school motivation among affected youth, underscoring the need for school psychologists to assess and intervene in behavioral-emotional domains for improved long-term independence.[151][150]

Palliative Approaches for Lethal Defects

Anencephaly, a severe neural tube defect characterized by the absence of major portions of the brain, calvarium, and scalp, is universally lethal, with affected infants exhibiting no potential for sustained extrauterine survival. Empirical data indicate that postnatal survival is typically limited to hours or days, with a first-year mortality rate approaching 100% due to the irreversible absence of cerebral hemispheres and brainstem dysfunction leading to respiratory failure and inability to maintain homeostasis.[152][153] Palliative approaches emphasize comfort care over aggressive interventions, aligning with the recognition that life-prolonging measures such as mechanical ventilation or nutritional support are futile and may prolong suffering without benefit.[154] Comfort care protocols for anencephalic infants prioritize symptom management, including hydration, pain relief via opioids if indicated, and thermal regulation to minimize distress during the brief postnatal period. Perinatal palliative care teams coordinate with families antenatally to prepare for delivery in a supportive setting, often involving skin-to-skin contact, baptism or memorial rituals if desired, and avoidance of invasive procedures like intubation or resuscitation.[155] Studies of parental experiences highlight that such approaches facilitate grief processing and family bonding, with mothers reporting empowerment through continued pregnancy and dignified end-of-life care rather than early termination.[156] Rare cases of extended survival beyond days, achieved through non-standard interventions like gastrostomy and ventilation, underscore ethical tensions but do not alter the consensus on non-viability, as they result in persistent coma-like states without neurological function.[154][152] Ethically, guidelines from medical bodies and bioethics literature advocate withholding treatments that merely delay inevitable death, framing the infant's personhood and dignity as warranting compassionate withdrawal from futile care. The Catholic Medical Association and similar frameworks assert that anencephalic infants deserve palliative measures appropriate to the dying, rejecting organ harvesting protocols due to concerns over hastening death and diagnostic uncertainties.[157] This stance counters proposals for experimental therapies, prioritizing causal realism: the defect's embryological origin precludes functional brain development, rendering curative intent biologically implausible.[153] Multidisciplinary involvement, including neonatologists, ethicists, and chaplains, supports informed parental decisions, with data showing reduced intensive care utilization and improved family satisfaction when palliative consults are integrated early.[158][159]

Prognosis and Outcomes

Survival Rates and Quality of Life

Survival rates for neural tube defects differ markedly by subtype. Anencephaly is incompatible with sustained life, with approximately 75% of cases resulting in stillbirth and the remainder dying within hours to days postnatally; long-term survival beyond infancy is unreported.[160] Encephaloceles have intermediate outcomes, with survival exceeding 80% to infancy but variable long-term prognosis depending on brain involvement.[161] Myelomeningocele, the severe form of spina bifida, yields high survival with intervention: first-year rates reach 92-96% in settings with folic acid fortification and neonatal surgery, rising to over 90% reaching adulthood.[162] [163] Median lifespan for these survivors has improved to 56 years as of 2022 U.S. data, reflecting better urologic and neurosurgical management.[164]
Neural Tube Defect TypeInfant Survival RateLong-Term Survival Notes
Anencephaly<1% beyond 1 weekFatal within days; no adulthood survivors[165]
Myelomeningocele90-96% to 1 year~90% to adulthood; median death age 56 years[166] [164]
Quality of life for myelomeningocele survivors centers on functional mobility and independence, modulated by lesion level and interventions. Lower motor levels (sacral/lumbar) enable higher ambulation rates, with National Spina Bifida Patient Registry data showing community ambulation in 40-60% of cases, often with orthotics, while higher lesions (thoracic) correlate with wheelchair reliance but preserved upper-body function.[167] Independence in self-care and transfers increases with age and therapy adherence, with longitudinal registry analyses indicating stable or improving mobility in over 70% of lower-lesion cohorts post-tethered cord management.[168] Employment and educational attainment reflect these outcomes, with many adults achieving partial to full independence despite variability.[169]

Long-Term Complications and Comorbidities

Individuals with myelomeningocele, the most common survivable form of spina bifida, experience a range of long-term neurological complications stemming from the initial neural tube closure failure and associated brainstem anomalies. Chiari II malformation, present in nearly all cases, involves downward displacement of the cerebellar vermis, pons, and medulla into the spinal canal, often leading to hydrocephalus requiring ventriculoperitoneal shunting and risks of syringomyelia or brainstem dysfunction.[170] [171] Tethered cord syndrome, resulting from abnormal fixation of the spinal cord, manifests in adulthood with progressive symptoms including back pain, lower extremity weakness, gait deterioration, and bladder or bowel dysfunction, affecting up to 20-30% of patients despite initial surgical untethering.[172] [173] Urological comorbidities are prevalent, with neurogenic bladder dysfunction occurring in 24-98% of adults, predisposing to urinary incontinence, recurrent urinary tract infections, vesicoureteral reflux, and chronic kidney disease in approximately 4-5% of cases due to high-pressure storage and inadequate emptying.[174] [175] Gastrointestinal issues, such as neurogenic bowel leading to chronic constipation and fecal incontinence, compound mobility limitations and contribute to overall reduced quality of life. Orthopedic deformities, including scoliosis (up to 44% symptomatic progression), hip dislocations, and foot anomalies, further impair ambulation and increase fall risks.[176] Latex allergy represents a significant iatrogenic comorbidity, with sensitization rates historically reaching 40-50% in spina bifida patients due to repeated exposures from surgical gloves, catheters, and medical devices during early interventions; clinical allergy manifests as urticaria, anaphylaxis, or contact dermatitis, necessitating latex-free environments.[177] [178] Reduced mobility and wheelchair dependence elevate obesity risks, as decreased energy expenditure and dietary challenges in this population promote excess weight gain, exacerbating pressure ulcers, respiratory issues, and cardiovascular strain.[179] [180] Cognitive impairments, including learning disabilities and executive function deficits, affect 20-50% and often correlate with shunt complications or lesion level, while skin breakdown from insensate areas heightens infection risks.[41] These interconnected issues underscore the need for lifelong multidisciplinary monitoring to mitigate secondary deteriorations.

Controversies and Debates

Efficacy Limits of Folic Acid Prevention

Despite periconceptional folic acid supplementation reducing neural tube defect (NTD) incidence by 50% to 70%, a residual 30% to 50% of cases persist, indicating inherent limitations in its preventive scope.[113][181] These gaps arise from factors such as suboptimal compliance, timing mismatches before neural tube closure at 28 days post-conception, and interactions with non-folate pathways, where supplementation fails to address all causal mechanisms.[182][183] In China, national folic acid programs initiated in the 1990s dramatically lowered NTD rates in high-prevalence rural northern regions by over 50% within five years, yet urban areas from 2013 to 2022 exhibited slower declines or stabilization, with prevalence hovering around 5-10 per 10,000 births despite supplementation efforts, attributed to lower baseline risks, variable uptake, and confounding socio-demographic shifts.[184][185] This plateau by the mid-2020s underscores that fortification alone cannot eliminate residual NTD burden in modernized settings with improved nutrition but persistent unmet needs.[186] Maternal pregestational diabetes exemplifies overrides, elevating NTD risk 2- to 10-fold through hyperglycemia-induced disruptions in folate transport and one-carbon metabolism, where standard 400 μg daily doses mitigate but do not fully counteract the teratogenic effects, as evidenced in cohort studies showing persistent elevated odds ratios even with supplementation.[187][188] Animal models confirm folic acid's partial efficacy in diabetic pregnancies, but human data reveal incomplete prevention due to impaired cellular uptake and competing metabolic stressors.[189] Epigenetic dysregulation further limits efficacy, with folic acid-resistant NTDs linked to abnormal DNA methylation and histone modifications in folate-sensitive genes, such as hypermethylation of developmental regulators like Brachyury (T gene), which supplementation fails to reverse in genetically susceptible cases.[190] Studies identify nucleotide synthesis defects bypassing folate pathways, preventable only by alternative precursors like inosine, highlighting that up to 20-30% of NTDs involve epigenetic or downstream metabolic barriers unresponsive to folic acid alone.[183][191]

Role of Selective Termination in Prevalence Statistics

Prenatal diagnosis of neural tube defects (NTDs) through ultrasound and maternal serum screening often prompts selective termination, which markedly influences prevalence statistics by distinguishing total diagnostic incidence from live birth rates. A systematic review of studies up to 1999 documented termination rates of 88% (95% CI: 86–90%) after prenatal diagnosis of anencephaly and 61% (95% CI: 58–65%) for spina bifida, reflecting the perceived severity of these conditions.[192] In England and Wales from 2007 to 2017, terminations accounted for approximately 75% of diagnosed NTD pregnancies, with 2,297 cases for anencephaly and 1,771 for spina bifida, correlating with declining live birth rates amid improved detection.[193] These rates vary by jurisdiction, gestational age at diagnosis, and socioeconomic factors, but consistently reduce observed live birth prevalence by 30–50% in regions with accessible screening and legal termination options.[194] The exclusion of terminated pregnancies from many registries skews trends, as live birth-based statistics may show apparent declines attributable to terminations rather than primary prevention alone. For example, in California from 1989 to 1991, live births and stillbirths represented only 48.4% of total anencephaly cases and 70.2% of spina bifida cases when including electively terminated fetuses, biasing risk estimates downward.[194] Incorporating terminated cases has been shown to increase reported prevalence by over 50% for NTDs and similar defects in population studies.[195] This methodological artifact complicates causal attribution in epidemiological analyses, such as those crediting folic acid fortification for NTD reductions, as heightened screening uptake coincides temporally with fortification programs.[196] Debates persist over diagnostic versus live birth metrics, with some researchers advocating for comprehensive registries that include all outcomes to accurately gauge NTD burden and prevention efficacy.[194] Critics of termination-inclusive data argue it inflates perceived incidence without altering viable birth risks, while others contend that live birth-only figures obscure the full scope of embryonic failures and undermine incentives for upstream interventions like nutritional optimization. Ethical considerations further color interpretations; for lethal defects like anencephaly, terminations are often framed as averting futile suffering, yet selective practices raise questions about diagnostic accuracy, parental autonomy, and potential societal pressures favoring termination for non-lethal NTDs like milder spina bifida.[197]

Genetic Determinism vs. Preventable Causes

Neural tube defects (NTDs) exhibit multifactorial inheritance, with heritability estimates ranging from 60% to 76% based on sibling regression and segregation analyses of affected pedigrees.[198][199] Familial recurrence risks for siblings of affected individuals are approximately 3-5%, substantially exceeding the general population prevalence of 0.5-1 per 1,000 births, indicating a significant genetic predisposition beyond sporadic environmental insults.[200][201] While periconceptional folic acid supplementation reduces NTD incidence by 50-70% through fortification and targeted dosing of 400-4,000 micrograms daily, it fails to prevent all cases, leaving a residual risk attributable to genetic variants in folate metabolism pathways such as MTHFR and other enzymes involved in one-carbon transfer.[181][113][202] This limitation underscores that public health campaigns emphasizing universal environmental interventions, like mandatory grain fortification since the late 1990s, achieve partial success but overlook how host genetics modulate responsiveness; for instance, certain mutations render neurulation failure inevitable despite adequate folate levels.[203][43] Empirical data thus refute strict genetic determinism, as modifiable risks including maternal folate status, obesity, diabetes, and valproate exposure demonstrably interact with polygenic susceptibility to tip causality toward defect formation.[204] However, over-optimism in narratives framing NTDs as predominantly preventable via lifestyle alone ignores heritability's explanatory power for non-responsive cases, where gene-environment interplay—rather than environment primacy—drives outcomes, as evidenced by persistent post-fortification rates of 5-6 per 10,000 in fortified regions.[51] Prioritizing genetic screening alongside supplementation could refine risk stratification, though current evidence cautions against assuming environmental fixes suffice universally.[198]

Recent Research Directions

Emerging Genetic Discoveries

Recent advances in genomics have shifted focus toward rare structural variants (SVs) in neural tube defects (NTDs), employing techniques like optical genome mapping (OGM) to detect deletions, duplications, inversions, and other rearrangements not captured by traditional SNP arrays or exome sequencing. A 2025 study analyzing 104 NTD cases identified diagnostic SVs with known pathogenic significance in 8% of cases and candidate SVs affecting NTD-related pathways in an additional 13%, highlighting the underappreciated role of large-scale genomic alterations in disease etiology.[52] These findings underscore that SVs disrupt critical developmental pathways beyond folate metabolism genes, contributing to the estimated 60-70% genetic heritability of NTDs where prior identification rates remained below 10%. In the planar cell polarity (PCP) pathway, essential for convergent extension during neural tube closure, a heterozygous deletion encompassing VANGL2 was detected in one case, aligning with prior evidence of copy number variations (CNVs) in PCP genes elevating NTD risk.[52] Similarly, duplications in HNRNPC, involved in RNA processing and linked to folate pathway perturbations, appeared in two cases, suggesting pathway-specific disruptions that impair cellular proliferation and adhesion.[52] Novel candidates include RMND5A, FOXD4, and RBBP4, where SVs were prioritized for their expression in neural tissues and functional roles in histone modification and transcriptional regulation during embryogenesis; these genes warrant functional validation to confirm causality.[52] Sequencing efforts have also implicated NUAK2 variants in NTD pathogenesis via the Hippo-YAP signaling pathway, which regulates cell adhesion and proliferation. A 2025 exome sequencing study identified a heterozygous missense variant (c.487G>A; p.Val163Met) in a family with sacral dimples, building on homozygous loss-of-function variants in fetuses with anencephaly and corroborated by Nuak2 knockout mice exhibiting exencephaly and spina bifida.[205] This suggests a semi-dominant inheritance model, expanding NTD genetics to monogenic forms independent of multifactorial folate interactions and emphasizing the need for broader genomic screening in familial cases.[205] Such discoveries, while promising, are limited by small cohort sizes and the absence of matched controls, necessitating replication in diverse populations to refine risk models.[52]

Epigenetic and Metabolic Pathways

Epigenetic regulation via histone post-translational modifications (PTMs) influences neural tube closure by modulating chromatin accessibility and gene expression in neuroepithelial cells. Acetylation of histone H3 at lysine 27 (H3K27ac) promotes active transcription, while trimethylation at the same residue (H3K27me3) represses genes essential for neural patterning; genome-wide profiling in human NTD tissues reveals dysregulated H3K27me3/H3K27ac balance, correlating with failure of neural fold elevation around embryonic day 25-28 in humans.[206] A 2024 review of human and animal data emphasizes that aberrant histone PTMs, including methylation and acetylation, disrupt spatiotemporal gene coordination required for convergence and fusion of neural folds, independent of primary genetic mutations.[207] One-carbon metabolism (OCM) pathways intersect with epigenetics by supplying S-adenosylmethionine (SAM), the universal methyl donor for histone and DNA modifications critical to neural development. Flux through folate-dependent OCM generates methyl groups for SAM synthesis, supporting de novo nucleotide production and methylation reactions; disruptions, such as reduced mitochondrial MTHFD1L activity, impair one-carbon partitioning, leading to hypomethylation and NTDs in mouse models at embryonic day 11.5.[208][209] In human cohorts, altered plasma biomarkers of OCM (e.g., elevated homocysteine, diminished folate cofactors) precede NTD occurrence, with quantitative assessments showing 1.5-2-fold deviations in affected pregnancies.[210] Maternal diabetes exacerbates NTD risk through metabolic perturbations that alter epigenetic landscapes, with hyperglycemia elevating O-linked β-N-acetylglucosamine (O-GlcNAc) modification on histones and transcription factors. This hyper-O-GlcNAcylation competes with phosphorylation, repressing genes like Pax3 involved in neural crest migration and tube closure; diabetic mouse embryos exhibit 3-5-fold increased NTD incidence by embryonic day 10.5, linked to mitochondrial dysfunction and oxidative stress disrupting OCM flux.[211][212] Human epidemiological data from 1989-2010 cohorts indicate a 2-10-fold elevated odds ratio for NTDs in diabetic pregnancies, attributable to dysregulated maternal metabolism overriding embryonic compensatory mechanisms.[126] These pathways highlight causal vulnerabilities where metabolic imbalances propagate via epigenetic reprogramming, amplifying developmental failure.[213]

References

  1. Neural Tube Defects - CDC
  2. Neural tube defects: a review of global prevalence, causes, and ...
  3. Genetic Epidemiology of Neural Tube Defects - PMC
  4. Folic acid and neural tube defects: Discovery, debate and the need ...
  5. CDC Grand Rounds: Understanding the Causes of Major Birth Defects
  6. Embryology, Neural Tube - StatPearls - NCBI Bookshelf - NIH
  7. Neural tube closure: cellular, molecular and biomechanical ...
  8. Formation of the Neural Tube - Developmental Biology - NCBI - NIH
  9. Neural Tube Defects - Medscape Reference
  10. Force-generating apoptotic cells orchestrate avian neural tube ...
  11. Neural Fold - an overview | ScienceDirect Topics
  12. The cellular dynamics of neural tube formation - Portland Press
  13. Spina Bifida: A Review of the Genetics, Pathophysiology and ...
  14. Neural tube defects: Different types and brief review of neurulation ...
  15. Myelomeningocele - StatPearls - NCBI Bookshelf - NIH
  16. Overview on Neural tube defects: from development to physical ...
  17. Comparison of two fetoscopic open neural tube defect repair ...
  18. [PDF] Role of Amniotic Fluid Toxicity in the Pathophysiology of ...
  19. Single surgeon case series of myelomeningocele repairs in a ...
  20. Efficiency of topical rifampin on infection in open neural tube defects
  21. Surgical treatment outcome of children with neural-tube defect
  22. V-Y Plasty or Primary Repair Closure of Myelomeningocele
  23. About Neural Tube Defects (NTDs) | NICHD
  24. Neural tube defects – disorders of neurulation and related ...
  25. Spina Bifida | National Institute of Neurological Disorders and Stroke
  26. Tethered cord syndrome - Bobby Jones CSF
  27. Spina Bifida Occulta Diagnosis & Treatment - NYC
  28. Spina bifida occulta - Cleveland Clinic
  29. Tethered Cord Syndrome (TCS) - StatPearls - NCBI Bookshelf - NIH
  30. Spina Bifida Occulta Is a Risk Factor for Spinal Cord Injury ... - NIH
  31. Adult-Onset tethered cord Syndrome: Case series from a ...
  32. Other Spinal Dysraphisms | PM&R KnowledgeNow - AAPM&R
  33. Spinal Dysraphisms: A New Anatomical–Clinicoradiological ...
  34. Tethered cord due to spina bifida occulta presenting in adulthood
  35. Typical lesions in the fetal nervous system - PubMed Central - NIH
  36. [PDF] BIRTH DEFECTS SURVEILLANCE - CDC Archive
  37. Encephalocele - StatPearls - NCBI Bookshelf - NIH
  38. Iniencephaly: Radiological and pathological features of a series of ...
  39. Neural Tube Defects (NTDs)
  40. Hydranencephaly - StatPearls - NCBI Bookshelf - NIH
  41. Spina Bifida - StatPearls - NCBI Bookshelf
  42. Global Birth Prevalence of Spina Bifida by Folic Acid Fortification ...
  43. A quest for genetic causes underlying signaling pathways ... - Frontiers
  44. Genome-wide investigation identifies a rare copy-number variant ...
  45. Optical genome mapping identifies rare structural variants in neural ...
  46. Genetics and development of neural tube defects - PMC
  47. Burden of Neural Tube Defects and Their Associated Factors in ...
  48. Risk factors of neural tube defects: A reality of Batna region in Algeria
  49. Mutations in VANGL1 Associated with Neural-Tube Defects
  50. Novel Mutations in VANGL1 in Neural Tube Defects - PMC - NIH
  51. Evaluation of common genetic variants in 82 candidate genes as ...
  52. Optical genome mapping identifies rare structural variants in neural ...
  53. Association Between Folate and Health Outcomes: An Umbrella ...
  54. Folic Acid Supplementation to Prevent Neural Tube Defects ...
  55. Birth prevalence of neural tube defects and associated risk factors in ...
  56. Neural Tube Defect Genes and Maternal Diabetes during Pregnancy
  57. Diabetes and Obesity-Related Genes and the Risk of Neural Tube ...
  58. Use of Antiepileptic Medications in Pregnancy in Relation to Risks of ...
  59. Risks of Congenital Malformations in Offspring Exposed to Valproic ...
  60. Valproic Acid in Pregnancy Revisited - PubMed Central
  61. Maternal, paternal, and neonatal risk factors for neural tube defects
  62. Mouse as a model for multifactorial inheritance of neural tube defects
  63. Human Neural Tube Defects: Developmental Biology, Epidemiology ...
  64. Nonsyndromic Neural Tube Defects: Genetic Basis and Genetic ...
  65. Association of the Maternal MTHFR C677T Polymorphism with ...
  66. Bringing clarity to the role of MTHFR variants in neural tube defect ...
  67. Gene Environment Interactions in the Etiology of Neural Tube Defects
  68. Folate deficiency reduced aberrant level of DOT1L-mediated histone ...
  69. Neural tube defects and epigenetics: role of histone post ... - PubMed
  70. Perspectives on folate with special reference to epigenetics and ...
  71. Original Article Risk Factors for Neural-Tube Defects Detected in Utero
  72. [EPUB] Neural tube defects among new borns: a cross-sectional study
  73. Risk factors for neural tube defects in the war and siege-affected ...
  74. Critical appraisal on neural tube defects and their complexities
  75. Gene-environment interactions underlying the etiology of neural ...
  76. Neural tube defects as a cause of death among stillbirths, infants ...
  77. Estimates of global and regional prevalence of neural tube defects ...
  78. Key Findings: Global Burden of Neural Tube Defects - CDC Archive
  79. Prevalence of neural tube defects and their associated factors in ...
  80. Birth prevalence of neural tube defects in eastern Africa
  81. The Global Burden of Neural Tube Defects and Disparities in ...
  82. Data and Statistics | Spina Bifida - CDC
  83. Tracking the Global Burden of Neural Tube Defects and Assessing ...
  84. Diagnosis and Management of Neural-Tube Defects Today
  85. Less decline than expected in rate of brain, spine defects after folic ...
  86. Impact of Folic Acid Fortification of the US Food Supply on the ...
  87. Reduction in Neural-Tube Defects after Folic Acid Fortification in ...
  88. Impact of folic acid fortification of the US food supply on ... - PubMed
  89. Global, regional, and national epidemiological trends in neural tube ...
  90. Trends of neural tube defects in urban China and effects of socio ...
  91. Prevalence of neural tube defects in England prior to the mandatory ...
  92. Surveillance Summaries Temporal Trends in the Incidence of Birth ...
  93. Maternal age is highly associated with non‐chromosomal congenital ...
  94. Association of low maternal education with neural tube defects in ...
  95. None
  96. Prenatal screening for neural tube defects: from maternal serum ...
  97. Diagnosis of Birth Defects - CDC
  98. Alpha Fetoprotein Maternal - Lab Test | Corewell Health Laboratory
  99. Screening for fetal aneuploidy and neural tube defects - PMC - NIH
  100. Neural Tube Defects Workup: Imaging Studies, Laboratory Studies
  101. Neural tube defects: Prenatal sonographic diagnosis - UpToDate
  102. Detection of neural tube defect in the first and second trimester of ...
  103. Ultrasound Evaluation of the Neural Tube | Article | GLOWM
  104. Prenatal Testing for Chromosomal Abnormalities and Neural Tube ...
  105. Common Tests During Pregnancy | Johns Hopkins Medicine
  106. Research progress on ultrasound and molecular markers for ...
  107. Diagnosing Spina Bifida in Children - NYU Langone Health
  108. Spina Bifida Clinical Presentation: History, Physical Examination
  109. Neural Tube Defect (Myelomeningocele) Postnatal Management
  110. Prevention of neural tube defects: results of the Medical Research ...
  111. Prevention of neural tube defects: Results of the Medical Research ...
  112. Prevention of the First Occurrence of Neural-Tube Defects by ...
  113. Folic Acid for the Prevention of Neural Tube Defects | Pediatrics
  114. Folic Acid Supplementation to Prevent Neural Tube Defects: US ...
  115. About Folic Acid - CDC
  116. Additional Opportunities to Prevent Neural Tube Defects with Folic ...
  117. Folate fortification and supplementation in prevention of folate ...
  118. Global heterogeneity in folic acid fortification policies ... - The Lancet
  119. Folic acid to reduce neonatal mortality from neural tube disorders
  120. Maternal obesity and risk of neural tube defects: a metaanalysis
  121. Does Obesity Increase the Risk of Having a Child with a Birth Defect?
  122. Maternal Obesity: A Focus on Maternal Interventions to Improve ...
  123. Association of Maternal Prepregnancy Diabetes and Gestational ...
  124. Association of maternal risk factors with the recent rise of neural tube ...
  125. Management of prepregnancy, pregnancy, and postpartum obesity ...
  126. Neural tube defects associated with maternal periconceptional ...
  127. [PDF] Genetic Epidemiology of Neural Tube Defects - CDC Stacks
  128. The recurrence risk for neural tube defects in the United States: A ...
  129. Recurrence risk after neural tube defects in a genetic counselling clinic
  130. Recurrence risks for neural tube defects in a genetic counseling ...
  131. Genetics of human neural tube defects - PMC - PubMed Central
  132. Genes related to neural tube defects and glioblastoma - Nature
  133. Closing in on Mechanisms of Open Neural Tube Defects
  134. Prenatal Genetic Testing and Screening: A Focused Review
  135. A Randomized Trial of Prenatal versus Postnatal Repair of ...
  136. Surgical Treatment of Neural Tube Defects - IntechOpen
  137. Spina bifida and neural tube defects - BMJ Best Practice
  138. Postnatal Surgical Correction of Myelomeningoceles: Preoperative ...
  139. Surgical treatment outcome of children with neural-tube defect
  140. A randomized trial of prenatal versus postnatal repair of ... - PubMed
  141. Prenatal Repair and Physical Functioning Among Children With ...
  142. Comparison of open fetal, fetoscopic and postnatal surgical repair ...
  143. Management of Myelomeningocele Study (MOMS) | ClinicalTrials.gov
  144. Multidisciplinary spina bifida clinic: the Chicago experience - PubMed
  145. Care coordination guidelines for the care of people with spina bifida
  146. Multidisciplinary management of people with spina bifida across the ...
  147. Mobility guidelines for the care of people with spina bifida - PMC - NIH
  148. Mobility Guideline - Spina Bifida Association
  149. The Impact of Family, Peer, and School Contexts on Depressive ...
  150. Cognitive, Behavioral and Educational Outcomes in Children Aged ...
  151. Mental Health Guideline - Spina Bifida Association
  152. Prolonged unassisted survival in an infant with anencephaly - NIH
  153. [PDF] Concepts of Personhood, Ethical Questions, and Nursing Care
  154. Life-Prolonging Therapies in a Case of Anencephaly: A Mother's Wish
  155. Perinatal palliative care: focus on comfort - PMC - NIH
  156. Providing Palliative Care to Neonates With Anencephaly ... - PubMed
  157. Moral Principles Concerning Infants with Anencephaly | USCCB
  158. A fetal diagnostic center's referral rate for perinatal palliative care
  159. Role of palliative care in fetal neurological consultations - NIH
  160. Anencephaly | Boston Children's Hospital
  161. Neural tube defects as a cause of death among stillbirths, infants ...
  162. Survival of Infants With Neural Tube Defects in the Presence of Folic ...
  163. Time to Death and Predictors Among Neonates with Neural Tube ...
  164. Spina Bifida Patients Are Living 15 Years Longer in 2022 Than in ...
  165. Survival in infants with anencephaly - PubMed
  166. What is Spina Bifida
  167. Factors Associated with Mobility Outcomes in a National Spina ... - NIH
  168. Factors Associated With Ambulation in Myelomeningocele - PubMed
  169. Long-Term Quality of Life for Patients with Spina Bifida
  170. Chiari Malformation Type 2 - StatPearls - NCBI Bookshelf - NIH
  171. Chiari Malformation: Practice Essentials, Problem, Epidemiology
  172. Tethered cord release: a long-term study in 114 patients - PubMed
  173. Tethered Cord Syndrome in Adulthood - PMC - NIH
  174. A snapshot of the adult spina bifida patient – high incidence of ...
  175. Urological Surveillance and Medical Complications in the United ...
  176. Spina Bifida Outcome: A 25-Year Prospective - Karger Publishers
  177. Latex allergy guidelines for people with spina bifida - PMC - NIH
  178. Latex allergy in spina bifida: At the turning point?
  179. Health Concerns of Adolescents and Adults With Spina Bifida
  180. Adults with spina bifida: A cross‐sectional study of health issues and ...
  181. [PDF] Folic Acid Guidelines - MN Dept. of Health
  182. Prevention of Neural-Tube Defects with Folic Acid in China
  183. Nucleotide precursors prevent folic acid-resistant neural tube ...
  184. Prevalence and Trends of Birth Defects — Five Counties, Shanxi ...
  185. Trends of neural tube defects in urban China and effects of socio ...
  186. Temporal trends in the prevalence of major birth defects in China
  187. Maternal Dietary Glycemic Intake and the Risk of Neural Tube Defects
  188. The impact of folic acid intake on the association between diabetes ...
  189. Folate Deficiency and Neural Tube Defects in Pregnancy
  190. Abnormal methylation caused by folic acid deficiency in neural tube ...
  191. The emerging role of epigenetic mechanisms in the etiology of ...
  192. Termination rates after prenatal diagnosis of Down syndrome, spina ...
  193. Trends in termination of pregnancy for neural tube defects in ...
  194. Impact of prenatal diagnosis and elective termination on prevalence ...
  195. Impact of prenatal diagnosis and elective termination on ... - PubMed
  196. Impact of Prenatal Diagnosis and Elective Termination on the ...
  197. Fetuses with Neural Tube Defects: ethical approaches and the role ...
  198. Gene Environment Interactions in the Etiology of Neural Tube Defects
  199. NEURAL TUBE DEFECTS (NTD): FAMILY STUDIES - Nature
  200. Epidemiology and genetics of neural tube defects: An application of ...
  201. Recurrence risks for neural tube defects in siblings of patients with ...
  202. Neural tube defects between folate metabolism and genetics - PMC
  203. Updated Estimates of Neural Tube Defects Prevented by Mandatory ...
  204. Folic Acid and the Prevention of Birth Defects - PubMed Central - NIH
  205. NUAK2 Pathogenic Variants Are Definitively Associated with Neural ...
  206. Distinct H3K27me3 and H3K27ac Modifications in Neural Tube ...
  207. Full article: Neural Tube Defects and Epigenetics: Role of Histone ...
  208. Folate-mediated one-carbon metabolism and neural tube defects
  209. Mitochondrial one‐carbon metabolism and neural tube defects
  210. Quantitative assessment of maternal biomarkers related to one ...
  211. Impact of protein O-GlcNAcylation on neural tube malformation in ...
  212. Maternal metabolism influences neural tube closure - PMC
  213. The interaction of maternal diabetes with mutations that affect folate ...
User Avatar
No comments yet.